XLO

Insider Trades

Name	Value	Action	Price	Current Price
Shannon James SamuelDirector $44k5k shares BuyMar 26, 2026 $8.79 --
Gilead Sciences, Inc.10 Percent Owner $3743.7M shares BuyFeb 13, 2026 $0.0001 --
Brennan Kevin M.SVP, FINANCE AND ACCOUNTING $1.2k1.8k shares SellJan 2, 2026 $0.6432 --
Frankenfield Christopher JamesChief Financial Officer $4.5k7k shares SellJan 2, 2026 $0.6432 --
Shannon James SamuelDirector $17k25k shares BuyJun 17, 2025 $0.6886 --
Shannon James SamuelDirector $31k45k shares BuyJun 16, 2025 $0.686 --

News

zacks.comCancer Stocks That Are Advancing the Future of Oncology Carezacks.comMay 18

zacks.comXilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimateszacks.comMay 12

globenewswire.comXilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updatesglobenewswire.comMay 12

globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.comMay 7

Trade XLO

About Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.

CEO: Rene Russo
IPO Date: Oct 22, 2021

Market Data

Open: $8.96
High: $9.22
Low: $7.82
Volume: 56.5K
Avg Volume: 45.4K
52W High: $12.74
52W Low: $6.47

Valuation

Market Cap: $58M
Enterprise Value: $-86M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-5.5M
Revenue: $44M
Net Income: $-35M
Cash: $138M
Debt: $7.0M

Events

EarningsAug 13

EPS est. -0.59